


## INTRODUCTION

- The HIV Prevention Trials Network (HPTN) 065 (TLC-Plus) study sought to evaluate the feasibility of an enhanced community-level test, link to care, plus treat strategy in the U.S., and efficacy of financial incentives for improving linkage to care and viral suppression.<sup>1</sup>
- We conducted baseline (2010-11) and follow-up (2013) surveys among ART-prescribing clinicians at sites participating in the HPTN 065 (TLC-Plus) study in the Bronx, NY and Washington, DC to assess:
  - » practices for recommending ART to their HIV-infected patients
  - » attitudes concerning early ART initiation to prevent HIV transmission
- During the 4-year period (2010-2013) between the two surveys, new scientific findings were published and recommendations for ART initiation were updated:
  - » HPTN 052 demonstrated dramatic reduction in sexual HIV transmission with ART use<sup>2</sup>
  - » The Department of Health and Human Services (DHHS) recommended universal ART for all HIV-infected persons in the U.S.<sup>3</sup>

## METHODS

- ART-prescribing clinicians at 39 HIV care sites in the Bronx, NY and Washington, DC participating in the HPTN 065 (TLC-Plus) study completed a brief anonymous 29-item internet survey.<sup>4</sup>
- Baseline and follow-up survey data were not linked by respondent.
- We used t-tests and Kruskal-Wallis tests to assess for statistical differences in distribution of responses across the two surveys.

Figure 1: Study Flow of HIV Clinician Recruitment and Follow-up in 2 US Cities



## RESULTS

Table 1: Demographic Characteristics of Respondents

Variable	Baseline (n=165)	Follow-up (n=141)	P-value
Female (%)	59.4	56.7	0.51
Median age (years)	47	47	0.73
White race/ethnicity (%)	66.1	61.7	0.28
Specialty physician (%)	33.3	41.8	0.51
Primary care physician (%)	32.1	25.5	0.51
Practicing in public clinic (%)	44.8	50.4	0.51
Median duration caring for HIV-infected patients (years)	13.3	15.0	0.11
ART training in past 3 months (%)	53.9	58.2	0.58

Table 2: Number of Patients Initiated on ART in Past 12 Months

	Baseline	Follow-up	P-value
<b>Estimated number of patients provider initiated on ART in the past year</b>			
Median [IQR] (no. of responses)	10 [5 - 30] (n=160)	20 [8 - 36] (n=138)	0.04
<b>Estimated number of patients initiated on ART with the main goal of making it less likely that they would pass on HIV to their partners</b>			
Median [IQR] (no. of responses)	0 [0 - 3] (n=147)	3 [0 - 8] (n=131)	<0.01

Table 3: Factors Influencing ART Initiation

	Baseline (n=165) (%)	Follow-up (n=141) (%)	P-value
<b>Would you generally recommend ART be initiated for a typical HIV-infected patient...?</b>			
With CD4 count ≤ 500 cells/mm <sup>3</sup>	55.8	68.1	0.04
Irrespective of CD4 cell count	14.5	68.1	<0.01
<b>Which factor would lead you to initiate ART earlier than you would otherwise?</b>			
Patient having unprotected sex with partner(s) of unknown HIV status	63.6	81.6	<0.01
Patient in an HIV discordant sexual partnership	75.2	87.2	0.01

Table 4: ART for High Risk Behaviors

	Baseline (n=165) (%)	Follow-up (n=141) (%)	P-value
<b>If a patient tells me that he or she is engaging in high risk behaviors, I am more likely to recommend initiating ART, irrespective of their CD4+ count.</b>			
Strongly agree	23.0	41.1	<0.01
Agree	47.9	44.0	
Disagree	24.8	9.9	
Strongly disagree	1.2	2.1	
Did not answer	3.0	2.8	

Table 5: ART for Community Benefit


	Baseline (n=165) (%)	Follow-up (n=141) (%)	P-value
<b>Early initiation of ART can slow the spread of HIV in a community by making patients less infectious to others</b>			
Strongly agree	64.8	87.9	<0.01
Agree	29.7	9.2	
Disagree	2.4	0.0	
Strongly disagree	0.0	0.0	
Did not answer	3.0	2.8	

## KEY RESULTS

- The percentage of providers who reported recommending ART initiation irrespective of CD4 cell count increased from baseline to follow-up (14.5% vs. 68.1%, p<0.01) as did the percentage who would initiate ART earlier for patients having unprotected sex with partners of unknown HIV status (63.6% vs. 81.6%, p<0.01) and for those in HIV-discordant sexual partnerships (75.2% vs. 87.2%, p<0.01).
- The percentage of providers who strongly agreed with the statement "Early initiation of ART can slow the spread of HIV in a community by making patients less infectious to others" also rose (64.8% to 87.9%, p<0.01).
- Providers reported initiating more patients on ART in the past year with the main goal of making it less likely that patients would transmit HIV to their sexual partners (median of zero vs. three patients, p<0.01).

Figure 2: ART for Reducing HIV Transmission (follow-up results, n = 141)

"Because ART reduces the risk of HIV transmission, I routinely recommend ART to my HIV-infected patients"



## SUMMARY and CONCLUSION

- In the follow-up survey, respondents were significantly more likely to prescribe ART:
  - » irrespective of CD4 status
  - » when patients reported unprotected sex
  - » for patients in HIV discordant relationships
- Almost 90% of respondents "strongly agreed" that ART can reduce transmission within a community (versus 65% at baseline)
- From 2011 to 2013, a greater percentage of ART-prescribing providers in the two jurisdictions supported initiating ART for all HIV-infected patients and using ART to prevent transmission, consistent with new scientific evidence and changes in HIV treatment recommendations during the conduct of HPTN 065.<sup>2,3</sup>

## REFERENCES

<sup>1</sup> Donnell et al. Use of HIV case surveillance system to design and evaluate site-randomized interventions in an HIV prevention study: HPTN 065. *Open AIDS J.* 2012;6:122-30.

<sup>2</sup> Cohen et al. Prevention of HIV-1 infection with early antiretroviral therapy. *NEJM* 2011; 365(6):493-505

<sup>3</sup> Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents <http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf>

<sup>4</sup> Kurth et al. Clinician Practices and Attitudes regarding Early Antiretroviral Therapy in the US. *JAIDS* 2012;61:e65-e69.

## ACKNOWLEDGMENTS

We sincerely thank the clinicians who participated in this survey.

HPTN 065 (TLC-Plus) Study is supported by NIAID, NIDA, and NIMH (Cooperative Agreement #UM1 AI068619; #UM1 AI068617) and the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, US Centers for Disease Control and Prevention

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy And Infectious Diseases, the National Institutes of Health, or the Centers for Disease Control and Prevention.